Large gap with delayed quotes
|
Last quote
04/25/2026
-
02:00:00
|
Bid
04/27/2026 -
14:57:03
|
Bid Volume |
Ask
04/27/2026 -
14:57:03
|
Ask Volume |
|---|---|---|---|---|
|
65.36
-1.23
(
-1.85% )
|
62.01
|
200 |
65.88
|
100 |
Analysis date: 24.04.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 31.03.2026.
Interest
Very weak
Very weak
One star since 24.04.2026.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 31.03.2026 at a price of 64.63.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 24.04.2026.
4wk Rel Perf
-3.93%
-3.93%
The four-week dividend-adjusted underperformance versus SP500 is 3.93%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 13.05.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.62%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.25%.
Mkt Cap in $bn
7.74
7.74
With a market capitalization between $2 & $8bn, HALOZYME THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
2.14
2.14
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
5.91
5.91
The estimated PE is for the year 2028.
LT Growth
12.67%
12.67%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
5
5
Over the last seven weeks, an average of 5 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
1
1
For 1% of index variation, the stock varies on average by 0.01%.
Correlation
0.01
0.01
Stock movements are totally independent of index variations.
Value at Risk
19.81
19.81
The value at risk is estimated at USD 19.81. The risk is therefore 30.31%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
28.07.2010
28.07.2010